Pharmacological Reduction of Right Ventricular Enlargement

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-06-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularacuteleftheartmri
  Phrases that lowered it: patientstrcopdasthmathe efficacy
• Design: factorial (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Sponsor's past termination rate: 9.7% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 10.7% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 42 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 68.5% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 127046 (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Sponsor's past trials: 185 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ertugliflozin for Functional Mitral Regurgitation NCT04231331 · started 2020 · scored riskier than 88% of active trials completed
• A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure NCT01966601 · started 2013 · scored riskier than 66% of active trials completed
• Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure NCT00608140 · started 2008 · scored riskier than 86% of active trials terminated
• Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve NCT02679261 · started 2016 · scored riskier than 41% of active trials completed
• Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction NCT05672134 · started 2023 · scored riskier than 58% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.